FINEOS Appoints New Non-Executive Director
17.10.2019 18:23:00 EEST | Business Wire | Press release
FINEOS Corporation Holdings plc (ASX:FCL), the leading core platform vendor for life, accident and health, is delighted to announce the appointment of Mr. David Hollander as an Independent Non-Executive Director, to the Board of FINEOS effective on and from 14 October 2019.
David is a global leader and experienced board member with over 35 years of experience in the insurance, technology and professional services industries. David, who is based in the U.S., most recently served as Global Insurance Leader for Ernst & Young LLP (EY), a professional services operation across 150 countries with US$31bn+ in revenues.
As EY Global Insurance Leader, David was responsible for leading a high performing team of 12,000 professionals and worked closely with the C-suite, senior management teams and board of directors of clients ranging from Fortune 100 insurance companies to early stage Insurtechs.
Prior to his role as Global Insurance Leader, David served as Advisory Leader for the EY Global Insurance practice, where he led the push into digital and technology transformation, including significant human capital investment and off-shore capability building, that drove headcount from approximately 2,500 professionals in 2011 to over 8,000 by 2018.
Prior to EY, David served as a member of the Board of Directors of Westfield Insurance, a top 40 U.S. insurance carrier, where he was a member of the Audit Committee and CEO Succession Committee. He also previously served as Chief Executive Officer of UNIRISX, a SaaS-based policy administration Insurtech solution based in the UK, where he established a track record of innovation and set up initial U.S. and global operations spanning 20+ countries.
David began his career with Accenture (NYSE: ACN), where he served in a variety of leadership and client service roles. During his seven-year tenure as Chief Executive Officer of Accenture’s Financial Services Solutions Group, David led the formation and build out of a 200-person global Insurance software company within Accenture, driving more than US$1bn in consulting and outsourcing pull through revenues, in addition to leading the acquisition and integration of a major life and annuity software provider. Other leadership roles included serving as Accenture’s Philadelphia Office Managing Partner, the Global Property & Casualty Insurance Leader and U.S. Life and Annuity Leader.
Commenting on David’s appointment, FINEOS Chairman, Ms. Anne O’ Driscoll said: “We are delighted to welcome David onto the FINEOS Board. He is a highly respected insurance industry leader with deep insights and expertise, particularly in the U.S. market. His experience strengthens the existing skillset of our Board and we look forward to working with him on our global growth plans. In addition to undertaking his normal Board duties, David will undertake additional strategic consultancy for the Board to help accelerate company growth, with particular focus on attracting key talent to join the FINEOS team.”
About FINEOS Corporation Limited
FINEOS is a leading provider of core systems for life, accident and health insurance carriers globally with 6 of the 10 largest group life and health carriers in the US as well as 6 of the 10 largest life and health carriers in Australia. With employees and offices throughout the world, FINEOS continues to scale rapidly, working with innovative progressive carriers in North America, Europe, and Asia Pacific.
The FINEOS Platform provides customers full end to end core administration for group, voluntary and individual across life, accident and health. The FINEOS Platform includes the FINEOS AdminSuite core product suite as well as add-on products, FINEOS Engage to support digital engagement and FINEOS Insight for analytics and reporting.
For more information, visit www.FINEOS.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191017005647/en/
Contact information
Victoria Jamison
Marketing Manager
FINEOS Corporation
+ 353 1 639 9700
victoria.jamison@FINEOS.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SMBC and Toshiba Jointly Develop New Equity Indices Using Advanced Quantum-Driven Technologies28.5.2026 04:00:00 EEST | Press release
Sumitomo Mitsui Banking Corporation (“SMBC”) and Toshiba Corporation (“Toshiba”) today announced the joint development of the SMBC/TOSHIBA Quantum Driven Diversified Japan Equity Index and the SMBC/TOSHIBA Quantum Driven Diversified U.S. Equity Index, new equity indices realized with advanced quantum-driven technologies. Collectively, the indices are referred to as “SMBC/TOSHIBA Quantum Diversified” (the “Indices”). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260519448161/en/ Toshiba’s Simulated Bifurcation Machine 1. Background and Objectives Equity investment is central to asset management, but it also carries the ever-present risk of abrupt and substantial market fluctuations driven by geopolitical developments, changes in economic policy, and other external factors. In uncertain markets, investors are constantly seeking innovations in risk diversification that can protect their assets from unexpected market shocks. SM
BeOne Medicines Announces Phase 3 HERIZON-GEA Data Published in NEJM and Presented at ASCO 202628.5.2026 00:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that data from HERIZON-GEA-01 were published in The New England Journal of Medicine and will be presented in an oral presentation (Rapid Oral Abstract: 4010) at the American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2026, in Chicago.The HERIZON-GEA-01 clinical trial evaluated ZIIHERA® (zanidatamab) plus chemotherapy, with and without TEVIMBRA® (tislelizumab), compared with the control arm of trastuzumab plus chemotherapy as first-line treatment for advanced/metastatic HER2+ gastroesophageal adenocarcinoma (GEA). Dr. Sun Young Rha, Professor of Medical Oncology at the Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea, senior author of the NEJM manuscript and first author of the ASCO abstract, said: “Results from the HERIZON-GEA-01 published in The New England Journal of Medicine and presented in an oral presentation at ASCO provide ne
Stallergenes Greer Foundation Celebrates Excellence in Allergy Innovation With 2025 Awards27.5.2026 18:22:00 EEST | Press release
The Stallergenes Greer Foundation, dedicated to advancing allergy research, fostering innovation and addressing environmental factors which impact allergies, is delighted to announce the recipients of the 2025 edition of its prestigious Science Awards for Allergy. Building on the success of the previous edition, this year’s awards recognise outstanding contributions to allergy research and patient engagement and allocate a total of €100,000 to support these initiatives. Four researchers have been selected by the Board as award recipients, each receiving €25,000 across two categories: Innovation In Treatment Awards Assoc. Professor Alexander Eggel, PhD, Department for Biomedical Research, University of Bern, and Department of Rheumatology and Immunology, University Hospital Bern, Switzerland, recognised for his research: “Improving diagnostic and therapeutic options for allergic patients”; Dr Janice A. Layhadi, PhD, Research Associate, National Heart and Lung Institute, Imperial College
Capchase Secures $200M+, as Demand for Vendor Financing in Enterprise Tech Deals Accelerates27.5.2026 17:00:00 EEST | Press release
Capchase, the leading vendor financing platform for enterprise tech, today announced $200M+ in incremental funding to scale its embedded financing infrastructure globally and deploy more AI-enabled features. The funding, a mix of debt warehouse facilities and equity backed by institutional investors, reflects market validation that vendor financing has become essential infrastructure for enterprise technology companies to sell hardware and software products. As global B2B buyers face tighter budgets and greater scrutiny over large, up-front purchases, financing demand is growing. The Market Shift: Financing as a Growth Lever for B2B Tech Companies The $1.3 trillion vendor financing market has been traditionally dominated by banks and other lenders that utilize multi-thread email chains to manual doc review for underwriting. Capchase replaces those bottlenecks with financing tech embedded directly into sales tools such as Salesforce, enabling 97% of lending applications to be vetted and
ClickHouse Tops $250M ARR and 4,000 Customers, Launches Claude-Powered Agents at Open House 202627.5.2026 16:00:00 EEST | Press release
ClickHouse today opened Open House 2026, its second annual user conference, with a set of announcements that mark one of the company's most active quarters since founding. ClickHouse’s serverless cloud offering has crossed over $250 million in annual run-rate revenue — more than triple a year ago — and added more than 1,000 net new customers since January, bringing its total to 4,000. To meet the demands of AI-era workloads, the company also launched ClickHouse Agents, a fully managed agentic analytics service powered by Anthropic's Claude; published CostBench, an open benchmark comparing the major cloud data warehouses on cost-performance; and introduced House Mates, its first formal partner program. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527813115/en/ ClickHouse Co-Founders (left to right): Yury Izrailevsky, Aaron Katz, Alexey Milovidov Growth When ClickHouse closed its $400 million Series D in January 2026, it
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
